Alpine Immune Sciences Inc ALPN:NASDAQ

Last Price$8.40NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$7.80 (1)
Ask (Size)$9.20 (4)
Day Low / HighN/A - N/A
Volume147.3 K
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

Alpine Immune Sciences Inc ( NASDAQ )

Price: $8.40
Change: -0.07 (0.83%)
Volume: 147.3 K
4:00PM ET 1/21/2022
 
 

Pieris Pharmaceuticals Inc ( NASDAQ )

Price: $3.40
Change: +0.06 (1.80%)
Volume: 975.1 K
4:00PM ET 1/21/2022
 
 

Cymabay Therapeutics Inc ( NASDAQ )

Price: $2.89
Change: +0.10 (3.58%)
Volume: 2.0 M
4:00PM ET 1/21/2022
 
 

CEL-SCI Corp ( NYSE MKT LLC )

Price: $5.64
Change: -0.18 (3.09%)
Volume: 1.2 M
6:30PM ET 1/21/2022
 
 

XOMA Corp ( NASDAQ )

Price: $21.34
Change: +0.45 (2.15%)
Volume: 44.4 K
4:00PM ET 1/21/2022
 

Read more news Recent News

Horizon Therapeutics Working With Alpine Immune Sciences to Develop Therapies for Autoimmune, Inflammatory Diseases
9:02AM ET 12/16/2021 MT Newswires

Horizon Therapeutics (HZNP) and Alpine Immune Sciences (ALPN) on Thursday entered into an exclusive agreement to develop novel protein-based therapies for...

-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Reports Q3 Revenue $8.5M
4:13PM ET 11/10/2021 MT Newswires

...

Insider Buy: Alpine Immune Sciences
9:26AM ET 9/22/2021 MT Newswires

Peter A. Thompson, 10% Owner, Director, on September 17, 2021, executed a purchase for 1,010,637 shares in Alpine Immune Sciences (ALPN) for $9,499,988....

Insider Sell: Alpine Immune Sciences
5:24PM ET 9/21/2021 MT Newswires

Jay Venkatesan, 10% Owner, Director, on September 17, 2021, sold 400,000 shares in Alpine Immune Sciences (ALPN) for $3,760,000. Following the Form 4...

Company Profile

Business DescriptionAlpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases; immuno-oncology; and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA. View company web site for more details
Address188 East Blaine Street
Seattle, Washington 98102
Phone+1.206.788.4545
Number of Employees48
Recent SEC Filing01/06/20224
Executive Chairman & Chief Executive OfficerMitchell H. Gold
President & Head-Research & DevelopmentStanford L. Peng
Finance DirectorThaedra Thullberry
Chief Financial Officer, Secretary & Senior VPJames Paul Rickey

Company Highlights

Price Open$8.35
Previous Close$8.47
52 Week Range$7.87 - 15.14
Market Capitalization$245.4 M
Shares Outstanding29.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/17/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.73
Beta vs. S&P 500N/A
Revenue$705.0 K
Net Profit Margin-169.03%
Return on Equity-58.85%

Analyst Ratings as of 10/14/2021

Buy
4
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset